Skip to main content
    U

    Ultragenyx (RARE)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $16.70
    +0.80 (+5.03%)

    Market Cap: $1.62B

    Last updated: Nov 17, 2026 at 4:37 PM ET

    Ultragenyx (RARE) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Ultragenyx (RARE) has a market cap of $1.62B and an enterprise value of $1.47B. It kept -71.69% of revenue as net income over the last 12 months.

    Total Valuation

    Enterprise value is 9.26% below the market cap, as cash exceeds debt.

    Market Cap$1.62B
    Enterprise Value$1.47B
    Latest price (Nov 17, 2026)$16.70

    Key Dates

    The next earnings report is expected on Feb 10, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateFeb 10, 2027 (expected)
    Last Earnings DateNov 3, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 0.20% in the quarter ended Sep 30, 2026 and grew 3.40% a year over 2 years.

    Shares Outstanding102.10M
    Shares Change (YoY)+2.30%
    Shares Change (QoQ)+0.20%
    Share Count Growth (2Y CAGR)+3.40%

    Valuation Ratios

    The price to sales ratio is 2.3x. Its year-end P/S ranged from 3.4x to 765.1x from 2017 to 2025.

    P/S Ratio2.3x
    Forward P/S2.1x

    Price Statistics

    The stock is down 49.52% over 52 weeks and trades 8.87% above its 50-day average.

    Beta (1Y)1.34
    52-Week Change-49.52%
    1-Month Change+10.82%
    3-Month Change-36.36%
    6-Month Change-25.61%
    5-Year Change-80.82%
    10-Year Change-72.71%
    Total Return (1Y)-49.52%
    Total Return (3Y CAGR)-25.24%
    Total Return (5Y CAGR)-26.43%
    Return vs SPY (1Y)-60.69%
    Max Drawdown (1Y)-64.75%
    Max Drawdown (3Y)-78.30%
    Sharpe Ratio (1Y)-0.70
    Correlation with SPY (1Y)0.19
    50-Day Average$15.34
    200-Day Average$22.45
    52-Week Range$12.73 to $39.89
    RSI (14 Days)53.8
    Average Volume (20 Days)3.74M

    The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 1.40x current liabilities, and total debt is 0.00x shareholder equity.

    Current Ratio1.40x
    Quick Ratio1.25x
    Debt / Equity0.00x
    Interest Coverage-5.67x

    Returns and Efficiency

    Return on Assets (ROA)-44.11%
    Return on Capital Employed (ROCE)-58.55%
    ROA (5Y Average)-38.34%
    ROIC (5Y Average)667.50%
    Asset Turnover0.61x
    Inventory Turnover2.12x
    Receivables Turnover3.99x
    Cash Conversion Cycle141 days

    Scores

    RARE has an Altman Z-Score of -5.68, in the distress zone below 1.81, and a Piotroski F-Score of 4 of 9, in the average band of 3 to 7.

    Altman Z-Score-5.68
    Altman Z ZoneDistress
    Piotroski F-Score4 of 9
    Piotroski StrengthAverage

    Income Statement

    Revenue of $730.28M over the last 12 months is up 15.80% from the 12 months before.

    Revenue$730.28M
    Revenue Growth (YoY)+15.80%
    Gross Profit$604.93M
    Operating Income-$467.28M
    Pretax Income-$529.69M
    Net Income-$523.56M
    EBITDA-$434.95M
    EBIT-$467.22M
    Reported EPS (TTM)-$4.89

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Cash and Equivalents$150.00M
    Total Debt$0
    Net Cash$150.00M
    Net Cash Per Share$1.47
    Working Capital$155.00M
    Shareholder Equity-$376.00M
    Tangible Book Value-$590.00M
    Total Assets$1.19B
    Total Liabilities$1.56B

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    After $4.94M of capital spending, operating cash flow left -$441.77M of free cash flow.

    Operating Cash Flow-$436.83M
    Capital Expenditures$4.94M
    Free Cash Flow-$441.77M
    FCF Per Share-$4.48
    Depreciation and Amortization$35.30M

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is -63.99%.

    Gross Margin82.84%
    Operating Margin-63.99%
    Pretax Margin-72.53%
    Net Margin-71.69%
    EBITDA Margin-59.56%
    EBIT Margin-63.98%
    FCF Margin-60.49%
    Gross Margin (5Y Average)89.47%

    Growth

    Revenue grew 22.81% a year over 3 years.

    Revenue Growth (3Y CAGR)+22.81%
    Revenue Growth (5Y CAGR)+19.95%

    Revenue and profit by year

    Dividends and Yields

    RARE does not pay a dividend. Its free cash flow yield is -25.91%.

    FCF Yield-25.91%
    Buyback Yield-0.13%
    Shareholder Yield-0.13%

    Peer Position

    Against 11 similar companies, RARE has the 9th highest P/S.

    P/S Ratio2.3x vs 6.4x median
    Revenue Growth (Trailing 4 Quarters, YoY)+15.80% vs +33.55% median

    Competitors compared

    Analyst Forecast

    Consensus estimates put revenue growth at 20.61% a year over the next 2 fiscal years.

    Revenue Growth Forecast (2Y CAGR)+20.61%

    Analyst estimates by year

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Frequently Asked Questions About RARE

    What is RARE's market cap?

    Ultragenyx has a market cap of $1.62B. Its enterprise value, which adds debt and subtracts cash, is $1.47B.

    How many shares of RARE are outstanding?

    Ultragenyx has 102.10M shares outstanding. The count is up 2.30% from a year earlier.

    Does RARE pay a dividend?

    No. Ultragenyx does not pay a dividend.

    How much debt does RARE have?

    Ultragenyx has $0 of total debt and $150.00M of cash and equivalents, a net cash position of $150.00M.